Myriad's Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk; FDA Approves JANUMET XR Print E-mail
By Mary Davila   
Thursday, 02 February 2012 20:12
Below is a look at some of the headlines for companies that made news in the healthcare sector on February 2, 2012.

Myriad Genetics, Inc. (Nasdaq: MYGN) announced a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," was presented on Thursday, February, 2, 2012 at the 2012 Genitourinary Cancers Symposium.

The study concluded that the Prolaris score, which analyzes the expression level of 46 cell cycle progression genes, demonstrated significant and unique prognostic ability in a contemporary cohort of men who had undergone radical prostatectomy, and accurately predicted their elevated risk for prostate cancer recurrence.


====


Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the FDA approved JANUMET^ XR (sitagliptin and metformin hydrochloride (HCl) extended-release) tablets, a new treatment for type 2 diabetes that combines sitagliptin, which is the active component of JANUVIA^ (sitagliptin), with extended-release metformin.

JANUMET XR provides a convenient once-daily treatment option for healthcare providers and patients who need help to control their blood sugar.



Also Thursday:



MissionIR today announces that its interview with Boyd Gentry, the president and chief executive officer of AdCare Health Systems (NYSE Amex: ADK), is now available online.

MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the "Company") announced financial results today for its first quarter ended December 31, 2011.

PHI Group, Inc. (OTCQB: PHIE) (PINKSHEETS: PHIE) announced today that Humex Medical Group, Inc. has signed an agreement with Tri Phuoc Co., Ltd, a Vietnamese company, to establish a stem cell center in Vietnam.

VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) has released its latest version of the VMS™ heart analysis system.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter